Physician profile
Christopher E Howson
NPI 1508129826
$114,152.45
in general payments reported to CMS, 2019-2025
33 companies · $33K in 2025
The $33K reported for 2025 was more than what 98% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $6,518 · 2021: $21K · 2022: $22K · 2023: $15K · 2024: $15K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Travel and Lodging: $7,346 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,350 · Food and Beverage: $5,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,150.00 |
| Travel and Lodging | $7,345.88 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,350.00 |
| Food and Beverage | $5,089.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $60,291.33 | 2019-2025 | Wavewriter Alpha Prime 16, Intracept, General - Therapies |
| Medtronic, INC. | $38,661.53 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Anteralign Spinal System With Titan Nanolock Surface Technology |
| Abbott Laboratories | $9,506.18 | 2022-2025 | Proclaim |
| Medtronic USA, INC. | $2,240.59 | 2019-2020 | |
| Relievant Medsystems, INC. | $1,219.99 | 2021-2023 | Intracept |
| Spr Therapeutics, INC | $440.73 | 2023-2025 | Sprint Pns System |
| Abbvie INC. | $248.46 | 2022-2025 | |
| Nevro Corp. | $207.23 | 2022-2024 | Senza |
| Spinal Simplicity, LLC | $161.31 | 2025 | Ha Minuteman G3-R |
| Allergan, INC. | $139.30 | 2019-2022 | |
| Vertos Medical, INC. | $121.62 | 2022 | |
| Depuy Synthes Sales INC. | $116.81 | 2019-2022 | |
| Saluda Medical Americas, INC. | $111.98 | 2023-2024 | Evoke Scs, Evoke |
| Vertex Pharmaceuticals Incorporated | $100.77 | 2024-2025 | |
| Ibsa Pharma INC. | $95.14 | 2022-2025 | Tirosint, Flector, Licart |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $61.59 | 2019-2021 | |
| Grt US Holding, INC. | $55.97 | 2022 | |
| Averitas Pharma INC. | $39.51 | 2024 | Qutenza |
| Sanofi-Aventis U.S. LLC | $36.15 | 2019 | |
| Electronic Waveform Lab, INC. | $33.94 | 2023 | |
| Pfizer INC. | $30.42 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.22 | 2022 | |
| Amgen INC. | $25.14 | 2019 | |
| Nalu Medical, INC. | $22.79 | 2025 | Nalu Neurostimulation System |
| Shionogi INC | $22.45 | 2019 | |
| Merz Pharmaceuticals, LLC | $22.35 | 2025 | Xeomin |
| Globus Medical, INC. | $20.39 | 2025 | Senza |
| Ipsen Biopharmaceuticals, INC | $19.62 | 2023 | Dysport |
| Tonix Medicines, INC. | $15.74 | 2025 | Tonmya |
| Biodelivery Sciences International, INC. | $14.85 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.40 | 2019 | |
| Lilly USA, LLC | $13.33 | 2019 | |
| Collegium Pharmaceutical, INC. | $12.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Howson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.